Relevant and even prescient commentary on news, politics and the economy.

Are Drug Companies Alone Responsible for the Prices We Pay for Medicines?

I had presented Part I and Part II a while back. Part III was difficult to present in a piece-meal way so for now I have set it aside. What is interesting about Part IV is I can beak it apart into segments, still maintain the flow of informatio, and present it in a logical […]

March 2024, Subsidy Enhancements Allow ~ Half of all Enrollees to be Eligible for Free Benchmark ACA Silver Coverage

It has been a while since I have commented on anything ACA related. This popped up in my in-box. I follow Andrew Sprung for the technical side of it. xpostfactoid’s Andrew and Charles Gaba at ACASignups are my go-to people on ACA healthcare and healthcare. To answer this question . . . how can it […]

Asking questions and dealing with the answers

One motivation to getting my genome sequenced was to see whether I had known risk alleles for dementia (spoiler alert: I don’t). My dad was diagnosed with frontotemporal lobe dementia a few years before he died. His brain biopsy after death returned a diagnosis of Alzheimers. He might have had both. One of the known […]

Direct-to-consumer MRIs and the democratization of health care information

Several years ago, I got my genome sequenced and obtained my variant call files, the tabulation of all differences between my gene sequences and the annotated human genome. Although my primary care physician was aware, I didn’t require his intermediation to obtain or interpret my genomics data. How I might react to adverse information was […]

Without swift action, the VA will continue ‘eliminating choice for millions of veterans’

by Jasper Craven Task & Purpose In mid-April, U.S. Sen. Jon Tester, a Montana Democrat, and Sen. Jerry Moran, a Kansas Republican, sent a letter to Secretary of Veterans Affairs Denis McDonough demanding to know why the agency was wounding itself.  Specifically, they worried about a series of seemingly contradictory eligibility and staffing policies. In […]

Medicare Advantage and Consolidation’s New Frontier – The Danger of “United Healthcare” for All

by Hayden Rooke-Ley, Soleil Shah, and Erin C. Fuse Brown New England Journal of Medicine Introduction The government will pay roughly $500 billion to insurance companies in 2024 to administer the Medicare Advantage program, including 23% more per beneficiary than it spends on traditional Medicare . . . equivalent to an extra $88 billion per year. Medicare Advantage plans cost […]

When a bug is a feature

As a subject in the Moderna phase III COVID vaccine trial, I wasn’t told whether I’d get the vaccine or a placebo. Indeed, neither my nurse nor the doctor overseeing the trial knew which subjects got which. It was a double-blind trial. 12 hours after the second jab, I started experiencing a headache, muscle and […]

The Elderly President’s Medicare Part D program Saves Money for Seniors and the Government

Continuing the ongoing implementation of President Biden’s prescription drug pricing law called the Inflation Reduction Act of 2022. The Centers for Medicare & Medicaid Services (CMS) released the final part one guidance for the new Medicare Prescription Payment Plan. Today’s guidance helps ensure that Medicare Part D plan sponsors can successfully implement the Medicare Prescription Payment Plan and effectively […]